**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 17065**

**Columns: ORIGINAL ARTICLE**

***Retrospective Cohort Study***

**Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury**

Lo wk *et al*. Impedance is better than pre-lung transplant reflux test

Wai-Kit Lo, Robert Burakoff, Hilary J Goldberg, Natan Feldman, Walter W Chan

**Wai-Kit Lo, Robert Burakoff, Natan Feldman, Walter W Chan,** Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women’s Hospital, Boston, MA 02115, United States

**Wai-Kit Lo,** Department of Gastroenterology, VA Boston Healthcare System, Boston, MA 02130, United States

**Wai-Kit Lo, Robert Burakoff, Hilary J Goldberg, Walter W Chan,** Harvard Medical School, Boston, MA 02115, United States

**Hilary J Goldberg,** Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, MA 02115, United States

**Author contributions:** Chan WW and Lo WK initiated study concepts and design; Lo WK, Feldman N and Goldberg HJ contributed to acquisition of data; Chan WW, Lo WK, Goldberg HJ and Burakoff R performed analysis and interpretation of data; Chan WW and Lo WK drafted the manuscript; Chan WW, Lo WK, Goldberg HJ and Burakoff R contributed to critical revision of manuscript for important intellectual content; Chan WW and Lo WK performed statistical analyses; and Chan WW provided administrative support and overall study supervision.

**Ethics approval:** The study was approved by the Partners Healthcare Institutional Review Board prior to inception.

**Informed consent:** Informed consent was waived with permission of the IRB board due to retrospective nature of the study, and low risk to participants.

**Conflict-of-interest:** The authors report no conflict of interest.

**Data sharing:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to:** **Walter W Chan, MD, MPH,** Brigham and Women’s Hospital, Division of Gastroenterology, Hepatology, and Endoscopy, 75 Francis Street, Boston, MA02115, United States. wwchan@partners.org

**Telephone:** +1-617-7326389

**Fax:** +1-617-5250338

**Received:** February 10, 2015

**Peer-review started:** February 10, 2015

**First decision:** April 13, 2015

**Revised:** April 15, 2015

**Accepted:**June 9, 2015

**Article in press:**

**Published online:**

**Abstract**

**Aim**: To evaluate pre-lung transplant acid reflux on pH-testing *vs* corresponding bolus reflux on multichannel intraluminal impedance (MII) in predicting early allograft injury.

**Methods**: This was a retrospective cohort study of lung transplant recipients who underwent pre-transplant combined MII-pH-testing at a tertiary care center from January 2007 to November 2012. Patients with pre-transplant fundoplication were excluded.Time-to-event analysis was performed using Cox proportional hazards model to assess associations between measures of reflux on MII-pH testing and early allograft injury.Area under the ROC curve (c-statistic) of the Cox model was calculated to assess the predictive value of each reflux parameter for early allograft injury. Six pH-testing parameters and their corresponding MII measures were specified a priori.The pH parameters included were upright, recumbent, and overall acid reflux exposure, elevated acid reflux exposure, total acid reflux episodes, and acid clearance time.The corresponding MII measures were upright, recumbent, and overall bolus reflux exposure, elevated bolus reflux exposure, total bolus reflux episodes, and bolus clearance time.

**Results**: 32 subjects (47% men, mean age: 55 years old) met the inclusion criteria of the study. Idiopathic pulmonary fibrosis (46.9%) represented the most common pulmonary diagnosis leading to transplantation.Baseline demographics, pre-transplant cardiopulmonary function, number of lungs transplanted (unilateral vs bilateral), and post-transplant proton pump inhibitor use were similar between reflux severity groups. The area under the receiver operating characteristic (ROC) curve, or c-statistic, of each acid reflux parameter on pre-transplant pH-testing was lower than its bolus reflux counterpart on MII in the prediction of early allograft injury. In addition, development of early allograft injury was significantly associated with three pre-transplant MII measures of bolus reflux, including overall reflux exposure (HR 1.18, 95% CI 1.01-1.36, p = 0.03), recumbent reflux exposure (HR 1.25, 95% CI 1.04-1.50, p = 0.01), and bolus clearance (HR 1.09, 95% CI 1.01-1.17, p = 0.02), but not with any pH-testing parameter measuring acid reflux alone.

**Conclusion**: Pre-transplant MII measures of bolus reflux perform better than their pH-testing counterparts in predicting early allograft injury post-lung transplantation.

**key words:**Gastroesophageal reflux; Lung transplant; Multichannel intraluminal impedance; pH-monitoring; Allograft injury

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastroesophageal reflux has been associated with poor lung transplant outcomes, including allograft injury and rejection. While ambulatory pH-testing only measures acid reflux, multichannel intraluminal impedance (MII) assesses total bolus reflux regardless of acidity. Comparison of pH-testing and MII measures of reflux in the prediction of lung transplant outcomes may improve and standardize pre-transplant reflux testing. Our study demonstrated that pre-transplant MII measures of bolus reflux perform better than their pH-testing counterparts in predicting early allograft injury post-lung transplantation.MII should be performed alongside pH testing for reflux assessment during pre-lung transplant evaluation.

Lo WK, Burakoff R, Goldberg HJ, Feldman N, Chan WW. Pre-lung transplant measures of reflux on impedance are superior to pH testing alone in predicting early allograft injury. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Lung transplantation remains a high risk solid-organ transplant modality[1], with gastroesophageal reflux disease (GERD) being a prevalent risk factor for post-transplant morbidity[2], resulting in development of bronchiolitis obliterans, chronic rejection, and death[3]. Evidence of inflammatory markers and pepsin in the bronchoalveolar fluid of subjects with acute rejection suggest that reflux and aspiration may play a role in early allograft injury[4-6], which are primary risk factors for chronic rejection[7-9] and graft failure.

While pre-transplant pH testing has been used with increased frequency given the association between severe acid reflux and poor transplant outcomes[3], no formal recommendation exists regarding the optimal reflux testing modality among lung transplant candidates.At issue is the possibility that multichannel intraluminal impedance and pH (MII-pH), which allows for assessment of gastroesophageal reflux regardless of pH, may provide additional data to help predict lung transplant outcomes compared to pH data alone, which can only evaluate acid reflux at low pH levels.Our group recently demonstrated that early allograft injury, comprised of both acute rejection and lymphocytic bronchiolitis, is associated with impedance measures of reflux severity on pre-transplant testing, including prolonged bolus clearance and increased distal reflux episodes[10].However, despite the association identified, additional benefits for using impedance over pH data alone could not be established, as comparison of impedance and pH parameters in predicting transplant outcomes was beyond the scope of that study.Therefore, in this follow-up study, we aim to compare the values of pre-transplant impedance and pH parameters in predicting early allograft injury in lung transplant recipients.We hypothesize that pre-transplant MII-pH measures of reflux severity are better than corresponding pH measures of acid reflux alone in the prediction of early lung transplant outcomes.

**MATERIALS AND METHODS**

This was a retrospective cohort study of adult subjects (age > 18) who underwent pre-operative MII-pH testing and received lung transplantation in 2007-2013 at a tertiary care center.Only patients undergoing initial primary lung transplantation were included.None received pre-transplant surgical or endoscopic management for reflux, including Nissen fundoplication.Subjects who did not survive beyond the first 30 d after transplant were excluded a priori, as such early mortality most likely reflects post-operative complications or hyperacute rejection unrelated to the present model of allograft injury under study.

Baseline characteristics (age at transplantation, gender, and race), pulmonary diagnosis, and results of standard pre-transplant cardiopulmonary testing were recorded.ABO compatibility was assured for all donors and recipients prior to transplantation.

***Pre-transplant MII-pH monitoring***

All subjects included in the study underwent MII-pH monitoring (Sandhill Scientific Inc, Highland Ranch, CO, United States) prior to transplantation, after an overnight fast.The system included a portable electronic datalogger and a catheter with two pH electrodes (0, 15 cm) and eight impedance electrodes (-3, -1, 1, 3, 5, 9, 11, 13 cm).The catheter was passed into the esophagus transnasally and positioned with the distal pH electrode 5 cm above the lower esophageal sphincter (LES).During the 24-hour study, subjects were asked to remain upright during the day and recumbent at night, and maintain normal scheduled activities.Meal periods were documented by the patient via the datalogger and were excluded from analysis.

Impedance and pH results were analyzed with the assistance of a dedicated software package (Bioview Analysis, version 5.6.3.0, Sandhill Scientific Inc, Highland Ranch, CO, United States).Parameters of interest were specified a priori and included six pH measures of acid reflux and their corresponding impedance measures of reflux severity.These measures were acid exposure time *vs* total bolus exposure time in upright, recumbent, and overall positions, expressed as a percentage of total time in reflux; total acid reflux episodes *vs* total bolus reflux episodes; and acid clearance time *vs* bolus clearance time, expressed in seconds.

Following MII-pH testing, patients proceeded to transplantation at different intervals pending individual disease progression and organ availability.

***Post-transplant care and diagnosis of early allograft injury***

After transplantation, patients received standard immunosuppressive therapy with azathioprine or mycophenolate, tacrolimus, and methylprednisolone[11].All patients underwent routine surveillance bronchoscopy with biopsy[12,13] on a standard post-transplant schedule (at 1, 3, 6, and 12 months), with additional diagnostic bronchoscopies following development of any clinical symptoms suggestive of infection or rejection, such as dyspnea, fever, or increased secretions.Biopsies were graded in accordance with The International Society of Heart and Lung Transplantation (ISHLT) standards[14]. The endpoint of early allograft injury was reached with the finding of rejection on transbronchial biopsy by ISHLT grading, with the sum of A and B grades greater than or equal to 2.Minimal rejection grades of A1B0 or A0B1 were counted as meeting the endpoint if the patient presented with suggestive clinical symptoms and received treatment with pulsed steroids.

***Statistical analysis***

Fisher’s exact test for binary variables and student’s *t*-test for continuous variables were performed to assess for differences between reflux severity groups.Survival analysis with the Cox proportional hazard model yielded hazard ratios with 95% confidence intervals for each specified pH variable and corresponding impedance measure of reflux severity, and its association with early allograft injury.Time-to-event was calculated from the date of transplant to date of biopsy diagnosing early allograft injury.Subjects not reaching the specified endpoint were censored at time of death, date of post-transplant anti-reflux surgery, or date of last evaluation by pulmonary transplant team, whichever was earliest.Performance of each parameter in predicting early allograft injury was calculated by area under the receiver operating characteristic (ROC) curve or c-statistic for the Cox models.All statistical analyses were performed using SAS 9.3 statistical package (SAS Institute Inc., Cary, NC, United States), with an additional macro for calculation of c-statistics for survival analysis data[15].

The study was approved by the Partners Healthcare Institutional Review Board prior to inception.

**RESULTS**

32 subjects (46.9% men, mean age 55 years) met inclusion criteria for the study, with a median follow-up of 1.3 years.The most common pulmonary diagnosis leading to transplantation was idiopathic pulmonary fibrosis (IPF), accounting for 46.9% of cases.17 patients (53.1%) underwent bilateral lung transplantation.There were 8 deaths detected overall, with 7 attributed to pulmonary complications including pneumonia (3 subjects), pulmonary malignancy (2 subjects), pulmonary hemorrhage (1 subject), and acute rejection (1 subject).Baseline cardiopulmonary characteristics were similar between reflux severity groups as defined by impedance measurement (Table 1).Although the elevated reflux group had more IPF diagnoses and a higher pre-transplant FEV1/FVC ratio, these were not associated with early allograft injury on Cox univariate modeling, accounting for timing of outcomes.Post-transplant PPI use also was not associated with early allograft injury in this cohort.Over the time course of the study, 16 subjects (50.0%, out of 32 subjects overall) developed early allograft injury, with 14 (53.8%, out of 26 subjects with > 1 year follow-up) diagnosed within the first year after transplantation. Univariate analyses performed on the six pre-specified pH and corresponding impedance parameters of reflux demonstrated significant associations between three impedance measures of reflux (total reflux exposure, recumbent reflux exposure, bolus clearance) and early allograft injury (Table 2).In comparing the areas under the ROC curve (c-statistic), every impedance parameter (measures of total reflux) was found to have greater predictive value for early allograft injury than the corresponding pH parameter alone (measures of acid reflux) (Table 3).

**DISCUSSION**

Our group has previously demonstrated that pre-transplant measures of reflux by impedance testing are associated with early allograft injury after lung transplantation[10].Based on that study, increased total reflux, not just acid reflux, may be associated with poorer early post-transplant outcomes.However, despite the association identified, an advantage for using impedance over pH-only testing in the prediction of post-transplant outcome was not established, as there has been no study directly comparing the predictive values of the two modalities in transplant cohorts.In the present study, we have specified six pH parameters of acid reflux severity and their corresponding impedance measures of total reflux that were obtained during MII-pH as part of pre-transplant evaluation.Notably, no pH-only measures of acid reflux were associated with the early allograft injury outcome, while three of the six corresponding impedance measures of total reflux were associated, suggesting that non-acid reflux may also play a role in allograft injury.Additionally, every impedance parameter was associated with a greater area under the ROC curve (c-statistic) than the corresponding pH-based parameter in predicting early allograft injury, suggesting that impedance data, and specifically the added information regarding non-acid reflux, may offer advantages over pH-only parameters in predicting lung transplant outcomes.Taken together, the MII parameters of bolus reflux exposure in the recumbent position and bolus clearance time are the best predictors of early allograft injury, based on the significant univariate results and the higher c-statistic values.

The literature on non-acid reflux in lung transplantation is sparse.One study documented that approximately one-third of patients with increased reflux parameters following transplantation had exclusively increased non-acid reflux[3], but there was no clear association with outcomes.A second study did identify an association between non-acid/total reflux and bronchiolitis obliterans[16], and similar to our study, no association was detected between abnormal acid reflux and rejection outcomes.However, only measures of acid and bolus reflux exposure were assessed in that study, which alone may not be sufficient to justify the use of impedance testing in lung transplant evaluation.Finally, bile acid aspiration has been associated with biomarkers of injury following lung transplantation, suggesting a possible pathway for allograft injury attributable to non-acid reflux[17].

The importance of documenting non-acid reflux and its possible contribution to lung transplant outcomes is twofold.First, treatments that target acid reflux, including various forms of anti-secretory medications, are less likely to have an effect on non-acid reflux[18-20].Thus, such treatments alone may be insufficient to completely mitigate the risk of allograft injury in lung transplant patients with reflux.Second, non-acid reflux may be a manifestation of other disease processes that require more specific evaluation and management, such as esophageal[21] or gastrointestinal motility disorders[22,23], which have yet to be studied widely in the lung transplant population.Review of medical records did not reveal a diagnosis of esophageal dysmotility or gastroparesis in any subjects in our cohort, though neither esophageal manometry nor gastric emptying study were routinely performed prior to transplantation.These results may demonstrate a need for additional testing or treatment options in transplant recipients.

Another challenge in the lung transplantation population includes absence of clear clinical guidelines regarding esophageal function testing prior to transplantation.While pH testing has been used increasingly in the pre-transplant assessment, impedance remains underutilized.Moreover, the value of impedance testing continues to be debated even in the management of typical GERD symptoms in non-transplant patients[24-26].The results of this study suggest that impedance may provide greater predictive value for post-transplant outcomes than conventional pH-based parameters for reflux.In particular, increased acid exposure time, defined by the proportion of time esophageal pH < 4 and the most commonly used outcome from pH-monitoring, performed poorly in predicting early allograft injury post-transplant (c-statistic = 0.39).However, when its impedance-equivalent (elevated total reflux exposure) was used, the predictive value of the result significantly improved (c-statistic = 0.77).These results also support the need for assessment of additional reflux-related factors that may be targets for intervention to improve lung transplant outcomes, such as obesity[27,28].Better pre-transplant reflux data that associate with post-transplant outcomes may help improve candidate risk assessment and planning of peri-transplant care.Therefore, our data would suggest a role for routine use of MII-pH as a standard part of pre-transplant evaluation for lung transplant candidates.

The strengths of this study include homogeneity of the study population, with meticulous record keeping and follow-up.Specifically, all patients underwent post-transplant care per standardized protocol, including routine histologic assessment of the allograft at regular intervals, thereby minimizing potential biases or any inter-provider variability in clinical management.Importantly, the overall rate of acute rejection within one year in our study corroborates published data, establishing generalizability of our patient cohort[29].Finally, mechanistic plausibility has been discussed in our prior publication[10], drawing from previous studies on biomarkers and lymphocytic infiltration to implicate reflux and aspiration in early allograft injury[4,30].

Limitations of the study include the small sample size, though within range of prior publications. The inclusion of transplant candidates receiving both MII and pH testing, as opposed to pH testing alone, may introduce external selection bias impacting generalizability, although demographics and clinical history appear homogeneous within the cohort as reported in Table 1.The study cohort also has a higher proportion of idiopathic pulmonary fibrosis patients than the overall lung transplant population[1], but a variety of primary pulmonary conditions was represented without significant differences between comparison groups.Additionally, the relatively small study size and low number of acute rejection and lymphocytic bronchiolitis events individually resulted in poor association between each individual outcome and pre-transplant MII-pH parameters.However, both markers of early allograft injury have been identified as major risk factors for development of subsequent BOS and are treated similarly in clinical practice with increased immunosuppression[29].Longer-term outcomes such as bronchiolitis obliterans could not be reliably assessed due to MII-pH testing becoming more available and widely used only in recent years.We hope that we will be able to assess such outcomes with continued recruitment, and in applying the findings from the present study.Finally, while our results support a relationship between reflux severity and early allograft injury, the actual pathways remain under investigation.

In summary, pre-transplant MII measures of bolus reflux are better predictors than their pH counterparts for development of early allograft injury post-lung transplantation.These findings suggest that non-acid reflux may play a role in the development of early allograft injury, leading to chronic rejection and allograft failure.MII-pH appears to be more valuable than pH-monitoring alone in pre-lung transplant reflux assessment, outcome risk stratification, and planning of peri-transplant care, and these findings would support the use of MII-pH rather than pH testing alone in this setting.Future research should focus on the optimal timing and application of MII-pH testing, and on treatments to manage non-acid and total reflux in lung transplant patients.

**comments**

***Background***

Gastroesophageal reflux (GER) has been associated with poorer outcomes following lung transplant. Patients may be predisposed to acute and chronic rejection, as GER may induce inflammatory cascades through aspiration. Current pre-transplant evaluations do not universally include standardized testing for reflux. While pH study monitors acid reflux, esophageal multichannel intraluminal impedance (MII) assesses total bolus reflux regardless of pH. Comparing the performance of pH *vs* MII testing in predicting post-transplant early allograft injury may help clarify the role of reflux on lung transplant outcomes and establish a standard in pre-transplant testing for reflux.

***Research frontiers***

Prior studies have suggested that the addition of MII to pH testing may increase the yield of the test for GER.However, more recent studies evaluating MII and pH studies with regards to treatment outcome for GER have demonstrated more conflicting results, with some showing a higher value for pH study-based acid parameters than MII measurements in predicting treatment outcomes for typical symptoms of GER.Comparative data between the two study modalities for extraesophageal manifestations of GER is even more scarce.

***Innovations and breakthroughs***

In this study, the authors compared the performance of pre-transplant acid reflux measures on pH testing *vs* corresponding bolus reflux parameters on MII in predicting early allograft injury after lung transplantation.This study is unique in directly comparing the predictive values of 2 testing modalities of reflux with regards to a clinical outcome for extraesophageal manifestation of GER.They found that pre-transplant MII measures of bolus reflux are better predictors than their pH counterparts for development of early allograft injury post-lung transplant. In particular, overall reflux exposure, recumbent reflux exposure, and prolonged bolus clearance were associated with increased early allograft injury.

***Applications***

Reflux assessment with MII should be routinely performed during pre-transplant evaluation, given its improved predictive qualities over those of pH testing alone and its association with post-transplant outcome.

***Terminology***

MII: Multichannel intraluminal impedance refers to the test that measures refluxing of gastric content into the esophagus regardless of pH level.Different substance (air, liquid, solid) has different conductance, which is inversely proportional to impedance.A drop in impedance is seen when liquid refluxes into the esophagus, as air normally carries a higher impedance.This allows monitoring of any refluxate advancing into the esophagus.Bolus reflux:Refers to any refluxate going from the stomach into the esophagus, regardless of acidity.

***Peer-review***

Important study.The discussion is well organized and the conclusions are appropriated.Right now, pH-testing is the gold standard for the study of the function of the esophagus and the measure of acid reflux.If these results are confirmed in posterior randomized and prospective studies, it is possible that MII could substitute pH-testing for preoperative study of acid reflux in patients in which a lung transplantation is going to be performed.

**REFERENCES**

1 **Christie JD**, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Kirk R, Rahmel AO, Stehlik J, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. *J Heart Lung Transplant* 2012; **31**: 1073-1086 [PMID: 22975097 DOI: 10.1016/j.healun.2012.08.004]

2 **Hadjiliadis D**, Duane Davis R, Steele MP, Messier RH, Lau CL, Eubanks SS, Palmer SM. Gastroesophageal reflux disease in lung transplant recipients. *Clin Transplant* 2003; **17**: 363-368 [PMID: 12868994 DOI: 10.1034/j.1399-0012.2003.00060.x]

3 **Blondeau K**, Mertens V, Vanaudenaerde BA, Verleden GM, Van Raemdonck DE, Sifrim D, Dupont LJ. Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. *Eur Respir J* 2008; **31**: 707-713 [PMID: 18057058 DOI: 10.1183/09031936.00064807]

4 **Fisichella PM**, Davis CS, Lowery E, Ramirez L, Gamelli RL, Kovacs EJ. Aspiration, localized pulmonary inflammation, and predictors of early-onset bronchiolitis obliterans syndrome after lung transplantation. *J Am Coll Surg* 2013; **217**: 90-100; discussion 100-1 [PMID: 23628225 DOI: 10.1016/j.jamcollsurg.2013.03.008]

5 **Stovold R**, Forrest IA, Corris PA, Murphy DM, Smith JA, Decalmer S, Johnson GE, Dark JH, Pearson JP, Ward C. Pepsin, a biomarker of gastric aspiration in lung allografts: a putative association with rejection. *Am J Respir Crit Care Med* 2007; **175**: 1298-1303 [PMID: 17413126 DOI: 10.1164/rccm.200610-1485oc]

6 **Davis CS**, Mendez BM, Flint DV, Pelletiere K, Lowery E, Ramirez L, Love RB, Kovacs EJ, Fisichella PM. Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation. *J Surg Res* 2013; **185**: e101-e108 [PMID: 23845868 DOI: 10.1016/j.jss.2013.06.011]

7 **Martinu T**, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. *Proc Am Thorac Soc* 2009; **6**: 54-65 [PMID: 19131531 DOI: 10.1513/pats.200808-080go]

8 **Girgis RE**, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, Reitz BA, Theodore J. Risk factors for the development of obliterative bronchiolitis after lung transplantation. *J Heart Lung Transplant* 1996; **15**: 1200-1208 [PMID: 8981205]

9 **Glanville AR**, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. *Am J Respir Crit Care Med* 2008; **177**: 1033-1040 [PMID: 18263803 DOI: 10.1016/j.healun.2006.11.149]

10 **Lo WK**, Burakoff R, Goldberg HJ, Feldman N, Chan WW. Pre-transplant impedance measures of reflux are associated with early allograft injury after lung transplantation. *J Heart Lung Transplant* 2015; **34**: 26-35 [PMID: 25444368 DOI: 10.1016/j.healun.2014.09.005]

11 **Knoop C**, Haverich A, Fischer S. Immunosuppressive therapy after human lung transplantation. *Eur Respir J* 2004; **23**: 159-171 [PMID: 14738248 DOI: 10.1183/09031936.03.00039203]

12 **Rademacher J**, Suhling H, Greer M, Haverich A, Welte T, Warnecke G, Gottlieb J. Safety and efficacy of outpatient bronchoscopy in lung transplant recipients - a single centre analysis of 3,197 procedures. *Transplant Res* 2014; **3**: 11 [PMID: 24917927 DOI: 10.1186/2047-1440-3-11]

13 **Dransfield MT**, Garver RI, Weill D. Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients. *J Heart Lung Transplant* 2004; **23**: 110-114 [PMID: 14734135 DOI: 10.1016/S1053-2498(03)00098-6]

14 **Stewart S**, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, Glanville A, Gould FK, Magro C, Marboe CC, McNeil KD, Reed EF, Reinsmoen NL, Scott JP, Studer SM, Tazelaar HD, Wallwork JL, Westall G, Zamora MR, Zeevi A, Yousem SA. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. *J Heart Lung Transplant* 2007; **26**: 1229-1242 [PMID: 18096473 DOI: 10.1016/j.healun.2007.10.017]

15 **Kremers W**. survcstd, 2008. Available from: URL http: //www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros. SAS 9.3

16 **King BJ**, Iyer H, Leidi AA, Carby MR. Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective. *J Heart Lung Transplant* 2009; **28**: 870-875 [PMID: 19716037 DOI: 10.1016/j.healun.2009.05.040]

17 **Neujahr DC**, Uppal K, Force SD, Fernandez F, Lawrence C, Pickens A, Bag R, Lockard C, Kirk AD, Tran V, Lee K, Jones DP, Park Y. Bile acid aspiration associated with lung chemical profile linked to other biomarkers of injury after lung transplantation. *Am J Transplant* 2014; **14**: 841-848 [PMID: 24666830 DOI: 10.1111/ajt.12631]

18 **Mainie I**, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. *Gut* 2006; **55**: 1398-1402 [PMID: 16556669 DOI: 10.1136/gut.2005.087668]

19 **Blonski W**, Vela MF, Castell DO. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy. *J Clin Gastroenterol* 2009; **43**: 816-820 [PMID: 19398927 DOI: 10.1097/MCG.0b013e318194592b]

20 **Clayton SB**, Rife CC, Singh ER, Kalbfleisch JH, Castell DO. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. *Dis Esophagus* 2012; **25**: 682-686 [PMID: 22292567 DOI: 10.1111/j.1442-2050.2011.01310.x]

21 **Kawamura O**, Hosaka H, Shimoyama Y, Kawada A, Kuribayashi S, Kusano M, Yamada M. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring. *Digestion* 2015; **91**: 19-25 [PMID: 25632912 DOI: 10.1159/000368766]

22 **Tavakkoli A**, Sayed BA, Talley NJ, Moshiree B. Acid and non-acid reflux in patients refractory to proton pump inhibitor therapy: is gastroparesis a factor? *World J Gastroenterol* 2013; **19**: 6193-6198 [PMID: 24115816 DOI: 10.3748/wjg.v19.i37.6193]

23 **Lidor AO**, Ensor CR, Sheer AJ, Orens JB, Clarke JO, McDyer JF. Domperidone for delayed gastric emptying in lung transplant recipients with and without gastroesophageal reflux. *Prog Transplant* 2014; **24**: 27-32 [PMID: 24598562 DOI: 10.7182/pit2014823]

24 **Bredenoord AJ**, Weusten BL, Timmer R, Conchillo JM, Smout AJ. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. *Am J Gastroenterol* 2006; **101**: 453-459 [PMID: 16464226 DOI: 10.1111/j.1572-0241.2006.00427.x]

25 **Patel A**, Sayuk GS, Gyawali CP. Acid-based parameters on pH-impedance testing predict symptom improvement with medical management better than impedance parameters. *Am J Gastroenterol* 2014; **109**: 836-844 [PMID: 24732868 DOI: 10.1038/ajg.2014.63]

26 **Patel A**, Sayuk GS, Gyawali CP. Parameters on Esophageal pH-Impedance Monitoring That Predict Outcomes of Patients With Gastroesophageal Reflux Disease. *Clin Gastroenterol Hepatol* 2015; **13**: 884-891 [PMID: 25158924 DOI: 10.1016/j.cgh.2014.08.029]

27 **Hajar N**, Castell DO, Ghomrawi H, Rackett R, Hila A. Impedance pH confirms the relationship between GERD and BMI. *Dig Dis Sci* 2012; **57**: 1875-1879 [PMID: 22451118 DOI: 10.1007/s10620-012-2131-6]

28 **Schneider JM**, Brücher BL, Küper M, Saemann K, Königsrainer A, Schneider JH. Multichannel intraluminal impedance measurement of gastroesophageal reflux in patients with different stages of morbid obesity. *Obes Surg* 2009; **19**: 1522-1529 [PMID: 18648896 DOI: 10.1007/s11695-008-9624-6]

29 **Martinu T**, Pavlisko EN, Chen DF, Palmer SM. Acute allograft rejection: cellular and humoral processes. *Clin Chest Med* 2011; **32**: 295-310 [PMID: 21511091 DOI: 10.1016/j.ccm.2011.02.008]

30 **Cohen S**, Saxena A, Waljee AK, Piraka C, Purdy J, Appelman H, McKenna B, Elmunzer BJ, Singal AG. Lymphocytic esophagitis: a diagnosis of increasing frequency. *J Clin Gastroenterol* 2012; **46**: 828-832 [PMID: 22751335 DOI: 10.1097/mcg.0b013e3182500de8]

**P-Reviewer:** Inamori, M, Priego P, Quigley EMM  **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Baseline characteristics demonstrating homogeneity of the pulmonary transplant study population**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Total(*n =* 32) | Normaldistal reflux exposure(*n =* 13) | Increaseddistal reflux exposure(*n =* 19) |
| Follow-up (yr), median | 1.3 |  |  |
| Male sex | 15 (46.9) | 7 (53.8) | 8 (42.1) |
| BMI, mean ± SD | 26.7 ± 4.97 | 26.7 ± 4.47 | 26.7 ± 5.40 |
| Age at transplant (yr), mean | 54.7 ± 10.8 | 57.6 ± 9.01 | 52.7 ± 11.7 |
| White Race | 30 (93.7) | 13 (100) | 17 (89.5) |
| Pulmonary Diagnosis |  |  |  |
|  IPF | 15 (46.9) | 3 (23.1) | 12 (63.2) |
|  COPD | 6 (18.7) | 3 (23.1) | 3 (15.8) |
|  CF | 6 (18.7) | 2 (15.4) | 4 (21.0) |
|  COP | 2 (6.25) | 2 (15.4) | 0 |
|  AAT | 1 (3.13) | 1 (7.69) | 0 |
|  Sarcoid  | 1 (3.13) | 1 (7.69) | 0 |
|  Other | 1 (3.13) | 1 (7.69) | 0 |
| Cardiac function, Baseline |  |  |  |
|  LVH |  |  |  |
| None | 27 (84.4) | 11 (84.6) | 16 (84.2) |
| Any | 5 (15.6) | 2 (15.4) | 3 (15.8) |
|  LVEF, mean ± SD | 0.59 ± 0.05 | 0.58 ± 0.06 | 0.60 ± 0.05 |
|  PCWP, mean ± SD | 9.97 ± 4.62 | 11.5 ± 4.99 | 8.89 ± 4.15 |
|  PVR1, mean ± SD | 224.4 ± 89.0 | 243.3 ± 100.1 | 210.0 ± 79.6 |
| Pulmonary Function, Baseline |  |  |  |
|  FVC | 1.91 ± 0.71 | 2.00 ± 0.84 | 1.85 ± 0.63 |
|  FVC, %-pred | 0.48 ± 0.14 | 0.50 ± 0.16) | 0.47 ± 0.12 |
|  FEV1 | 1.22 ± 0.60 | 1.07 ± 0.67 | 1.32 ± 0.54 |
|  FEV1, %-pred | 0.39 ± 0.18 | 0.33 ± 0.17 | 0.43 ± 0.17 |
|  FEV1/FVC | 0.65 ± 0.24 | 0.54 ± 0.24 | 0.73 ± 0.21 |
|  |  |  |  |
| Lungs Transplanted |  |  |  |
|  Unilateral | 15 (46.9) | 7 (53.8) | 8 (42.1) |
|  Bilateral | 17 (53.1) | 6 (46.1) | 11 (57.9) |
| Post-transplant PPI | 24 (75.0) | 10 (76.9) | 14 (73.7) |
|  |  |  |  |
| Deaths, all cause | 8 (25.0) | 2 (15.4) | 6 (31.6) |
| Deaths, pulmonary-related | 7 (21.9) | 2 (15.4) | 5 (26.3) |
| Early Allograft Injury | 16 (50.0) | 5 (38.5) | 11 (57.9) |
| BOS | 2 (6.25) | 1 (7.69) | 1 (5.26) |

1PVR was not measured in 2 subjects. BMI: Body mass index; IPF: Idiopathic pulmonary fibrosis; COPD: Chronic obstructive pulmonary disease; CF: Cystic fibrosis; COP: Cryptogenic organizing pneumonia; AAT: Alpha-1-antitrypsin deficiency; LVH: Left ventricular hypertrophy; LVEF: Left ventricular ejection fraction; PCWP: Pulmonary capillary wedge pressure; PVR: Pulmonary vascular resistance; FVC: Forced vital capacity; %-pred: Percent of predicted value; FEV1: Forced expiratory volume in 1 second; PPI: Proton pump inhibitor; BOS: Bronchiolitis obliterans syndrome.

**Table 2 Comparison of Cox univariate analyses of pH parameters of acid reflux and corresponding impedance measures of total reflux**

|  |  |  |
| --- | --- | --- |
| pH parameter of acid reflux | Univariate hazard ratio for time to acute rejection (95%CI) | *p*-value |
| Acid reflux exposure, upright | 1.01 (0.93-1.09) | 0.87 |
| Acid reflux exposure, recumbent | 1.06 (0.92-1.21) | 0.42 |
| Acid reflux exposure, overall | 1.03 (0.93-1.15) | 0.52 |
| Elevated acid reflux exposure (> 4.2%) | 1.06 (0.92-1.21) | 0.93 |
| Total acid reflux episodes | 1.00 (0.97-1.03) | 0.90 |
| Acid clearance | 1.00 (1.00-1.00) | 0.13 |
| Impedance parameter of total reflux | **Univariate hazard ratio for time to acute rejection (95%CI)** | ***p*-value** |
| Total reflux exposure, upright | 1.11 (0.98-1.25) | 0.11 |
| Total reflux exposure, recumbent | 1.25 (1.04-1.50) | **0.011** |
| Total reflux exposure, overall | 1.18 (1.01-1.36) | **0.031** |
| Elevated total reflux exposure (> 1.4%) | 1.88 (0.65-5.42) | 0.24 |
| Total reflux episodes | 1.01 (1.00-1.02) | 0.20 |
| Bolus clearance | 1.09 (1.01-1.17) | **0.021** |

1Note statistically significant results in impedance measures of total bolus reflux.

**Table 3 Area under the receiver operating characteristic curve or c-statistic comparing prediction value of pH-testing and corresponding impedance measures of reflux for early allograft injury**

|  |  |
| --- | --- |
| pH parameter of reflux | Area under ROC/ Harrell’s c-stat |
| Acid reflux exposure, upright | 0.58 |
| Acid reflux exposure, recumbent | 0.69 |
| Acid reflux exposure, overall | 0.61 |
| Elevated acid reflux exposure (> 4.2%) | 0.39 |
| Total acid reflux episodes | 0.60 |
| Acid clearance | 0.64 |
| Impedance Parameter of Reflux | **Area under ROC/ Harrell’s c-stat** |
| Total reflux exposure, upright | 0.63 |
| Total reflux exposure, recumbent | 0.74 |
| Total reflux exposure, overall | 0.67 |
| Elevated total reflux exposure (> 1.4%) | 0.77 |
| Total reflux episodes | 0.64 |
| Bolus clearance  | 0.74 |

Note that all values deriving from impedance measures are greater than from pH measures, suggesting that impedance data are better predictors.